This company has been acquired
The company may no longer be operating, as it has been acquired. Find out why through their latest events.
Surface Oncology Crecimiento futuro
Future controles de criterios 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for Surface Oncology.
Información clave
9.9%
Tasa de crecimiento de los beneficios
9.9%
Tasa de crecimiento del BPA
| Crecimiento de los beneficios de Biotechs | 24.8% |
| Tasa de crecimiento de los ingresos | 75.6% |
| Rentabilidad financiera futura | n/a |
| Cobertura de analistas | Low |
| Última actualización | 08 Sep 2023 |
Actualizaciones recientes sobre el crecimiento futuro
Recent updates
Forecast: Analysts Think Surface Oncology, Inc.'s (NASDAQ:SURF) Business Prospects Have Improved Drastically
Nov 07
Analysts Just Made A Major Revision To Their Surface Oncology, Inc. (NASDAQ:SURF) Revenue Forecasts
Aug 08Surface Oncology GAAP EPS of -$0.46 misses by $0.01
Aug 03Surface Oncology: Neither Novartis, Nor GSK Or ARKG Is Able To Stop The Decline
May 25News Flash: Analysts Just Made A Dazzling Upgrade To Their Surface Oncology, Inc. (NASDAQ:SURF) Forecasts
May 11Does Surface Oncology (NASDAQ:SURF) Have A Healthy Balance Sheet?
Feb 23Surface Oncology: If Novartis, GlaxoSmithKline And ARK See Promise, So Do I
Jan 18Is Surface Oncology (NASDAQ:SURF) A Risky Investment?
Nov 11Surface Oncology: Staying The Course
Oct 24Surface Oncology: A Diverse, But Early Pipeline
Jul 13Is Surface Oncology (NASDAQ:SURF) Using Too Much Debt?
Jun 07Surface Oncology EPS beats by $0.04, beats on revenue
May 05Here's What Surface Oncology, Inc.'s (NASDAQ:SURF) Shareholder Ownership Structure Looks Like
Mar 15Does Surface Oncology (NASDAQ:SURF) Have A Healthy Balance Sheet?
Feb 16
Surface Oncology: Early Stage Cancer-Specific Company With Novel Assets
Dec 09What Kind Of Shareholders Hold The Majority In Surface Oncology, Inc.'s (NASDAQ:SURF) Shares?
Dec 08Surface Oncology shares rise 13% on Fast Track tag for SRF388
Nov 11Previsiones de crecimiento de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
|---|---|---|---|---|---|
| 12/31/2025 | 16 | -75 | N/A | N/A | 2 |
| 12/31/2024 | N/A | -90 | N/A | N/A | 2 |
| 12/31/2023 | N/A | -90 | N/A | N/A | 1 |
| 6/30/2023 | N/A | -93 | -84 | -84 | N/A |
| 3/31/2023 | N/A | -90 | -60 | -59 | N/A |
| 12/31/2022 | 30 | -64 | -60 | -60 | N/A |
| 9/30/2022 | 30 | -66 | -54 | -54 | N/A |
| 6/30/2022 | 31 | -63 | -50 | -50 | N/A |
| 3/31/2022 | 31 | -57 | -67 | -67 | N/A |
| 12/31/2021 | 3 | -78 | -62 | -62 | N/A |
| 9/30/2021 | 90 | 13 | 26 | 26 | N/A |
| 6/30/2021 | 90 | 17 | 31 | 31 | N/A |
| 3/31/2021 | 89 | 21 | 27 | 27 | N/A |
| 12/31/2020 | 126 | 59 | 30 | 30 | N/A |
| 9/30/2020 | 39 | -24 | -56 | -56 | N/A |
| 6/30/2020 | 39 | -25 | -60 | -60 | N/A |
| 3/31/2020 | 40 | -28 | -58 | -57 | N/A |
| 12/31/2019 | 15 | -55 | -62 | -60 | N/A |
| 9/30/2019 | 25 | -44 | -63 | -61 | N/A |
| 6/30/2019 | 26 | -44 | -61 | -58 | N/A |
| 3/31/2019 | 28 | -35 | -65 | -63 | N/A |
| 12/31/2018 | 59 | -7 | -15 | -13 | N/A |
| 9/30/2018 | 52 | -18 | -15 | -14 | N/A |
| 6/30/2018 | 53 | -15 | -12 | -11 | N/A |
| 3/31/2018 | 57 | -13 | 21 | 22 | N/A |
| 12/31/2017 | 13 | -45 | -14 | -12 | N/A |
| 9/30/2017 | 12 | -36 | -13 | -11 | N/A |
| 12/31/2016 | 7 | -17 | N/A | 41 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: SURF is forecast to remain unprofitable over the next 3 years.
Beneficios vs. Mercado: SURF is forecast to remain unprofitable over the next 3 years.
Beneficios de alto crecimiento: SURF is forecast to remain unprofitable over the next 3 years.
Ingresos vs. Mercado: SURF is forecast to have no revenue next year.
Ingresos de alto crecimiento: SURF is forecast to have no revenue next year.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Insufficient data to determine if SURF's Return on Equity is forecast to be high in 3 years time